Kinarus Therapeutics (SIX: KNRS)

Currency in CHF

Last close As at 26/05/2023


0.00 (−7.69%)

Market capitalisation


Based in Switzerland, Kinarus Therapeutics is a clinical-stage pharmaceutical company focused on advancing lead candidate KIN001 in inflammatory, fibrotic and/or viral infection-related conditions.

Upon availability of new funding, Kinarus plans to start a Phase II study in wet age-related macular degeneration, backed by preclinical data suggesting potential benefit in reducing choroidal neovascularisation lesions and in idiopathic pulmonary fibrosis. Having shown in vitro antiviral activity against many COVID-19 variants, KIN001 is currently being assessed in the KINFAST Phase II study in ambulatory COVID-19 patients.



Equity Analyst

Pooya Hemami

Analyst - Healthcare

Key Management

  • Dr. Alexander Bausch


  • Subhasis Roy


Balance Sheet

Forecast net debt (CHFm)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 26.5 (21.5) (82.3)
Relative 26.3 (23.1) (82.3)
52 week high/low CHF0.1/CHF0.0


Kinarus has announced that it has entered into a CHF1.5m strategic convertible loan agreement with ChaoDian (Hangzhou) Investment Management, an investment company based in China. The CHF1.5m subordinated loan has a three-year fixed term and does not bear any interest, and is convertible to Kinarus shares at a fixed conversion price of CHF0.01 per share. In addition to supporting Kinarus’s financial position, the company indicates the loan agreement forms the basis for future discussions on the development and commercialisation of KIN001 for the treatment of idiopathic pulmonary fibrosis (IPF) in China. While discussions are preliminary and no deal or licensing arrangement can be assured at this stage, we are encouraged that KIN001 is attracting interest from potential partners and view this development as supportive of the underlying premise behind the potential anti-fibrotic and anti-inflammatory effects of KIN001.

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (fd) (CHFc) P/E (x) P/CF (x)
2020A 0.0 (1.5) (1.5) (31.17) N/A N/A
2021A 0.0 (5.1) (4.9) (0.41) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free